NASDAQ:ATYR Atyr PHARMA (ATYR) Stock Price, News & Analysis $4.32 -0.11 (-2.48%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$4.39 +0.07 (+1.62%) As of 02/21/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Atyr PHARMA Stock (NASDAQ:ATYR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Atyr PHARMA alerts:Sign Up Key Stats Today's Range$4.30▼$4.6650-Day Range$3.03▼$4.4452-Week Range$1.42▼$4.66Volume1.77 million shsAverage Volume987,059 shsMarket Capitalization$362.63 millionP/E RatioN/ADividend YieldN/APrice Target$18.60Consensus RatingBuy Company OverviewaTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.Read More… Atyr PHARMA Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreATYR MarketRank™: Atyr PHARMA scored higher than 56% of companies evaluated by MarketBeat, and ranked 573rd out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingAtyr PHARMA has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAtyr PHARMA has only been the subject of 4 research reports in the past 90 days.Read more about Atyr PHARMA's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Atyr PHARMA are expected to grow in the coming year, from ($0.91) to ($0.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atyr PHARMA is -4.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atyr PHARMA is -4.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtyr PHARMA has a P/B Ratio of 2.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Atyr PHARMA's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.66% of the float of Atyr PHARMA has been sold short.Short Interest Ratio / Days to CoverAtyr PHARMA has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Atyr PHARMA has recently increased by 8.52%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAtyr PHARMA does not currently pay a dividend.Dividend GrowthAtyr PHARMA does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.66% of the float of Atyr PHARMA has been sold short.Short Interest Ratio / Days to CoverAtyr PHARMA has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Atyr PHARMA has recently increased by 8.52%, indicating that investor sentiment is decreasing significantly. News and Social Media2.7 / 5News Sentiment0.89 News SentimentAtyr PHARMA has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Atyr PHARMA this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for ATYR on MarketBeat in the last 30 days. This is a decrease of -58% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Atyr PHARMA to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Atyr PHARMA insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,138.00 in company stock.Percentage Held by InsidersOnly 3.70% of the stock of Atyr PHARMA is held by insiders.Percentage Held by Institutions61.72% of the stock of Atyr PHARMA is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Atyr PHARMA's insider trading history. Receive ATYR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atyr PHARMA and its competitors with MarketBeat's FREE daily newsletter. Email Address ATYR Stock News HeadlinesAtyr PHARMA (NASDAQ:ATYR) Stock Rating Upgraded by Leerink PartnrsFebruary 21 at 3:15 AM | americanbankingnews.comAtyr PHARMA (NASDAQ:ATYR) Now Covered by Analysts at Leerink PartnersFebruary 20 at 1:43 AM | americanbankingnews.comAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what he might do next. And one widely followed Boston based think tank is stepping forward with their official playbook.February 22, 2025 | Altimetry (Ad)aTyr Pharma's SWOT analysis: efzofitimod's potential drives stock outlookFebruary 17, 2025 | msn.comRBC Capital Keeps Their Buy Rating on aTyr Pharma (ATYR)February 14, 2025 | markets.businessinsider.comaTyr Pharma CFO Broadfoot sells $4,740 in stockFebruary 6, 2025 | msn.comAtyr Pharma's general counsel Nancy Denyes sells $3,398 in stockFebruary 6, 2025 | msn.comHere's Why We're Watching aTyr Pharma's (NASDAQ:ATYR) Cash Burn SituationJanuary 30, 2025 | finance.yahoo.comSee More Headlines ATYR Stock Analysis - Frequently Asked Questions How have ATYR shares performed this year? Atyr PHARMA's stock was trading at $3.62 on January 1st, 2025. Since then, ATYR shares have increased by 19.3% and is now trading at $4.32. View the best growth stocks for 2025 here. How were Atyr PHARMA's earnings last quarter? Atyr PHARMA INC (NASDAQ:ATYR) released its quarterly earnings results on Thursday, November, 7th. The company reported ($0.23) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by $0.01. Who are Atyr PHARMA's major shareholders? Atyr PHARMA's top institutional shareholders include Federated Hermes Inc. (17.47%), Point72 Asset Management L.P. (5.82%), Tikvah Management LLC (2.93%) and Woodline Partners LP (2.01%). View institutional ownership trends. How do I buy shares of Atyr PHARMA? Shares of ATYR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Atyr PHARMA own? Based on aggregate information from My MarketBeat watchlists, some other companies that Atyr PHARMA investors own include ChargePoint (CHPT), Plug Power (PLUG), Chemomab Therapeutics (CMMB), Curaleaf (CURLF), Daré Bioscience (DARE), Jiuzi (JZXN) and Adial Pharmaceuticals (ADIL). Company Calendar Last Earnings11/07/2024Today2/22/2025Next Earnings (Estimated)4/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ATYR Previous SymbolNASDAQ:ATYR CUSIPN/A CIK1339970 WebN/A Phone(858) 731-8389Fax858-731-8394Employees53Year FoundedN/APrice Target and Rating Average Stock Price Target$18.60 High Stock Price Target$35.00 Low Stock Price Target$9.00 Potential Upside/Downside+330.6%Consensus RatingBuy Rating Score (0-4)3.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,390,000.00 Net MarginsN/A Pretax Margin-27,155.32% Return on Equity-79.44% Return on Assets-59.16% Debt Debt-to-Equity Ratio0.02 Current Ratio5.41 Quick Ratio5.41 Sales & Book Value Annual Sales$235,000.00 Price / Sales1,543.10 Cash FlowN/A Price / Cash FlowN/A Book Value$1.54 per share Price / Book2.81Miscellaneous Outstanding Shares83,942,000Free Float80,836,000Market Cap$362.63 million OptionableOptionable Beta1.10 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:ATYR) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atyr PHARMA INC Please log in to your account or sign up in order to add this asset to your watchlist. Share Atyr PHARMA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.